BSX

SEC source: 0001225208-22-000109 · doc4.xml · nonDerivative · entry 1

Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,059

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

SEC source: 0001225208-22-000108 · doc4.xml · derivative · entry 3

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,614 shares

Expires 2021-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

F1 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

SEC source: 0001225208-22-000108 · doc4.xml · nonDerivative · entry 2

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,391

SEC source: 0001225208-22-000108 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,223

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

SEC source: 0001225208-22-000107 · doc4.xml · derivative · entry 4

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,175 shares

Expires 2021-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

F1 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

SEC source: 0001225208-22-000107 · doc4.xml · nonDerivative · entry 2

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,158

SEC source: 0001225208-22-000107 · doc4.xml · nonDerivative · entry 1

Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,924

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

SEC source: 0001225208-22-000106 · doc4.xml · derivative · entry 3

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,193 shares

Expires 2021-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

F1 · derivative.exercise_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

F1 · derivative.expiration_date: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

SEC source: 0001225208-22-000106 · doc4.xml · nonDerivative · entry 2

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,379

SEC source: 0001225208-22-000106 · doc4.xml · nonDerivative · entry 1

Brennan Daniel J. · CIK 0001595612 · EVP and CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 276,436

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 21, 2019, the reporting person was awarded a target number of performance share units under the Company's 2019 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2019 adjusted free cash flow measured against its 2019 financial plan over the one-year performance period ending December 31, 2019 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 24, 2020, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2021.

SEC source: 0001225208-21-015271 · doc4.xml · nonDerivative · entry 1

Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,243

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-21-015180 · doc4.xml · derivative · entry 5

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 42,934 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

SEC source: 0001225208-21-015180 · doc4.xml · derivative · entry 4

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,997 shares

Expires 2022-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.

SEC source: 0001225208-21-015180 · doc4.xml · nonDerivative · entry 3

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.47 to $40.31, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-015180 · doc4.xml · nonDerivative · entry 2

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,988

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-015180 · doc4.xml · nonDerivative · entry 1

Pierce David A · CIK 0001529751 · EVP Pres MedSurg

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,991

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-015058 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,609

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-014510 · doc4.xml · derivative · entry 5

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,298

Underlying: Common Stock · 649 shares

Expires 2023-12-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant.

SEC source: 0001225208-21-014510 · doc4.xml · nonDerivative · entry 4

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,153

SEC source: 0001225208-21-014510 · doc4.xml · nonDerivative · entry 3

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 133,449

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-013899 · doc4.xml · nonDerivative · entry 1

WICHMANN DAVID S · CIK 0001268489 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · price: Represents the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $41.79 to, $42.09, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001225208-21-013896 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,930

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-22-000112 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,046,922

SEC source: 0001225208-21-013443 · doc4.xml · derivative · entry 5

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 330,268

Underlying: Common Stock · 66,054 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

SEC source: 0001225208-21-013443 · doc4.xml · derivative · entry 4

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 134,988 shares

Expires 2022-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.

SEC source: 0001225208-21-013443 · doc4.xml · nonDerivative · entry 3

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,081,822

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.77 to $43.42, inclusive. The reporting person undertakes to provide upon request by the U.S. Securties and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-013443 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,282,864

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-013443 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,216,810

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-013239 · doc4.xml · nonDerivative · entry 1

Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,692

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-013131 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,251

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-012913 · doc4.xml · derivative · entry 6

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 396,322

Underlying: Common Stock · 66,054 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

SEC source: 0001225208-21-012913 · doc4.xml · derivative · entry 5

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,988

Underlying: Common Stock · 134,988 shares

Expires 2022-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.

SEC source: 0001225208-21-012913 · doc4.xml · nonDerivative · entry 4

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,081,822

F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.02 to $43.68, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-012913 · doc4.xml · nonDerivative · entry 3

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,185,026

F2 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.02 to $43.01, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-012913 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,282,864

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-012913 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,216,810

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-012801 · doc4.xml · derivative · entry 3

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,394

Underlying: Common Stock · 3,393 shares

Expires 2022-10-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 2, 2018, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 2, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-21-012801 · doc4.xml · nonDerivative · entry 2

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,692

SEC source: 0001225208-21-012801 · doc4.xml · nonDerivative · entry 1

Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-21-012786 · doc4.xml · nonDerivative · entry 1

Olson Scott · CIK 0001816850 · SVP & Pres, Rhythm Management

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,762

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.

SEC source: 0001225208-21-012419 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,573

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-012144 · doc4.xml · derivative · entry 5

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 462,376

Underlying: Common Stock · 66,053 shares

Expires 2023-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant.

SEC source: 0001225208-21-012144 · doc4.xml · derivative · entry 4

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 269,976

Underlying: Common Stock · 134,988 shares

Expires 2022-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.

SEC source: 0001225208-21-012144 · doc4.xml · nonDerivative · entry 3

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,081,822

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $44.34 to $44.71, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-21-012144 · doc4.xml · nonDerivative · entry 2

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,282,863

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-012144 · doc4.xml · nonDerivative · entry 1

Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,216,810

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-011927 · doc4.xml · nonDerivative · entry 1

Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,419

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.

SEC source: 0001225208-21-014510 · doc4.xml · nonDerivative · entry 2

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,800

SEC source: 0001225208-21-014510 · doc4.xml · nonDerivative · entry 1

Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,935

SEC source: 0001225208-21-011514 · doc4.xml · nonDerivative · entry 1

Carruthers Wendy · CIK 0001563565 · SVP, Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,894

F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.